Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus + Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00736970Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2008
- Primary completion
- Jan 2011
- Modality
- Classical Binding Small Molecules
01
Overview
A Phase 2 trial of ridaforolimus in breast cancer, sponsored by Merck & Co.. Started Jul 2008; status: completed.
02
Drugs
ridaforolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00736970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00736970.